EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense

Xiaohui Ju, Ziqiao Wang, Pengcheng Wang, Wenlin Ren, Yanying Yu, Yin Yu, Bin Yuan, Jingwei Song, Xiaochun Zhang, Yu Zhang, Chang Xu, Boxue Tian und 3 weitere

mBio · 2023

DOI: 10.1128/mbio.01373-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2023. Verfasst von Xiaohui Ju und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tsinghua University , Beijing, China. Hauptthemen laut MEDLINE: COVID-19, Middle East Respiratory Syndrome Coronavirus. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Natural Science Foundation of China, BMSTC | Beijing Municipal Natural Science Foundation, National Key research and Development Plan of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent causing the global pandemic of COVID-19. SARS-CoV-2 genome encodes a main protease (nsp5, also called Mpro) and a papain-like protease (nsp3, also called PLpro), which are responsible for processing viral polyproteins to assemble a functional replicase complex. In this study, we found that Mpro of SARS-CoV-2 can cleave human MAGED2 and other mammalian orthologs at Gln-263. Moreover, SARS-CoV and MERS-CoV Mpro can also cleave human MAGED2, suggesting MAGED2 cleavage by Mpro is an evolutionarily conserved mechanism of coronavirus infection in mammals. Intriguingly, Mpro from Beta variant cleaves MAGED2 more efficiently than wild type, but Omicron Mpro is opposite. Further studies show that MAGED2 inhibits SARS-CoV-2 infection at viral replication step. Mechanistically, MAGED2 is associated with SARS-CoV-2 nucleocapsid protein through its N-terminal region in an RNA-dependent manner, and this disrupts the interaction between SARS-CoV-2 nucleocapsid protein and viral genome, thus inhibiting viral replication. When MAGED2 is cleaved by Mpro, the N-terminal of MAGED2 will translocate into the nucleus, and the truncated MAGED2 is unable to suppress SARS-CoV-2 replication. This work not only discovers the antiviral function of MAGED2 but also provides new insights into how SARS-CoV-2 Mpro antagonizes host antiviral response. IMPORTANCE Host factors that restrict severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain elusive. Here, we found that MAGED2 can be cleaved by SARS-CoV-2 main protease (Mpro) at Gln-263. SARS-CoV and MERS-CoV Mpro can also cleave MAGED2, and MAGED2 from multiple species can be cleaved by SARS-CoV-2 Mpro. Mpro from Beta variant cleaves MAGED2 more efficiently efficiently than wild type, but Omicron is the opposite. MAGED2 depletion enhances SARS-CoV-2 infection, suggesting its inhibitory role in SARS-CoV-2 infection. Mechanistically, MAGED2 restricts SARS-CoV-2 replication by disrupting the interaction between nucleocapsid and viral genomes. When MAGED2 is cleaved, its N-terminal will translocate into the nucleus. In this way, Mpro relieves MAGED2' inhibition on viral replication. This study improves our understanding of complex viral-host interaction and provides novel targets to treat SARS-CoV-2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Middle East Respiratory Syndrome CoronavirusAnimalsHumansAntiviral AgentsSARS-CoV-2Coronavirus 3C ProteasesNucleocapsid ProteinsMammalsAntigens, NeoplasmAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

MAGED2SARS-CoV-2cleavagemain proteasenucleocapsid proteinviral replication

Substanzen

Antiviral Agents3C-like proteinase, SARS-CoV-2Coronavirus 3C ProteasesNucleocapsid ProteinsMAGED2 protein, humanAntigens, NeoplasmAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • School of Medicine, Tsinghua University , Beijing, China.
  • Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Biosafety Level 3 Laboratory, Fudan University , Shanghai, China.
  • CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences , Beijing, China.
  • School of Pharmaceutical Sciences, Tsinghua University , Beijing, China.

ORCID-Profile: Yi Shi, Rong Zhang, Qiang Ding

Förderung

  • MOST | National Natural Science Foundation of China
  • BMSTC | Beijing Municipal Natural Science Foundation
  • National Key research and Development Plan of China
  • China Postdoctoral Science Foundation | Postdoctoral Research Foundation of China
  • Shuimu Tsinghua Scholar Program

Zitieren

APA

Ju, X., Wang, Z., Wang, P., Ren, W., Yu, Y., Yu, Y., Yuan, B., Song, J., Zhang, X., Zhang, Y., Xu, C., Tian, B., Shi, Y., Zhang, R., & Ding, Q. (2023). SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense. mBio. https://doi.org/10.1128/mbio.01373-23

Vancouver

Ju X, Wang Z, Wang P, Ren W, Yu Y, Yu Y, et al. SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense. mBio. 2023. doi:10.1128/mbio.01373-23

BibTeX
@article{Ju2023,
  author = {Ju, Xiaohui and Wang, Ziqiao and Wang, Pengcheng and Ren, Wenlin and Yu, Yanying and Yu, Yin and Yuan, Bin and Song, Jingwei and Zhang, Xiaochun and Zhang, Yu and Xu, Chang and Tian, Boxue and Shi, Yi and Zhang, Rong and Ding, Qiang},
  title = {SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense},
  journal = {mBio},
  year = {2023},
  doi = {10.1128/mbio.01373-23}
}
Kostenlos starten →